Compare Ascendis Pharma A/S (ASND) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Krispy Kreme Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Krispy Kreme Inc trades at $3.41 (market cap $593.06M). The key difference: Ascendis Pharma A/S is far larger — about 29.9× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DNUT | |
|---|---|---|
Market Cap | $17.74B | $593.06M |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $4.70 |
52-Week Low | $163.32 | $2.92 |
Enterprise Value | $18.11B | $1.79B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Krispy Kreme (DNUT) trades at $3.44, up 0.58% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -33.36% net margin and -58.92% ROE, though revenue remains stable near $1.5B. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat forecasts. Analyst sentiment is cautiously optimistic with 50% buy ratings, while technical indicators point to resistance near $4.
Outlook hinges on execution of capital-light expansion and cost controls. Risks include persistent losses and high debt, but potential upside exists if turnaround initiatives boost margins. Investors should weigh analyst optimism against weak cash flow trends and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
